Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC

PHASE2RecruitingINTERVENTIONAL
Enrollment

81

Participants

Timeline

Start Date

May 30, 2023

Primary Completion Date

May 30, 2025

Study Completion Date

May 30, 2026

Conditions
HNSCC
Interventions
DRUG

Danvatirsen

Danvatirsen is a STAT3 targeting drug.

DRUG

Pembrolizumab

Pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2

Trial Locations (32)

10029

RECRUITING

Mount Sinai, New York

11794

RECRUITING

Stony Brook Cancer Center, Stony Brook

21201

NOT_YET_RECRUITING

University of Maryland Baltimore, Greenebaum Comprehensive Cancer Center, Baltimore

29605

RECRUITING

Prisma Health Cancer Institute, Greenville

30308

RECRUITING

Emory University Hospital Midtown, Atlanta

33176

RECRUITING

Miami Cancer Institute, Miami

44106

RECRUITING

University Hospitals Cleveland, Cleveland

45219

RECRUITING

The Christ Hospital Cancer Center, Cincinnati

45229

RECRUITING

University of Cincinnati Medical Center, Cincinnati

49201

RECRUITING

Dong-A University Hospital, Busan

52727

RECRUITING

Gyeongsang National University Hospital, Jinju

60612

RECRUITING

University of Illinois Cancer Center, Chicago

66204

RECRUITING

AMR Kansas City Oncology, Merriam

66205

RECRUITING

University of Kansas Medical Center, Westwood

70809

RECRUITING

Mary Bird Perkins Cancer Center, Baton Rouge

75390

RECRUITING

UT Southwestern Medical Center/Simmons Comprehensive Cancer Center, Dallas

80045

RECRUITING

University of Colorado Hospital (UCH) Anschutz Cancer Pavilion, Aurora

85719

RECRUITING

The University of Arizona Cancer Center, Tucson

89169

RECRUITING

Comprehensive Cancer Centers of Nevada, Las Vegas

90024

RECRUITING

University of California Los Angeles, Westwood, Los Angeles

90505

RECRUITING

TMPN Hunt Cancer Care, Torrance

92617

RECRUITING

University of California Irvine (UCI), Irvine

07960

RECRUITING

Morristown Medical Center, Morristown

602-702

RECRUITING

Kosin University College of Medicine - Kosin University Gospel Hospital (KUGH), Busan

02841

RECRUITING

Korea University Medical Center (KUMC), Seoul

Unknown

RECRUITING

The Catholic University of Korea - Eunpyeong St. Mary's Hospital, Seoul

RECRUITING

Saint James's University Hospital (SJUH) - St James's Institute of Oncology, Leeds

RECRUITING

The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool

EC1A 7BE

RECRUITING

Barts Health MHS Trust (Barts and The London NHS Trust) - St Bartholomew's (Barts) Hospital, London

SW3 6JJ

RECRUITING

The Royal Marsden NHS Foundation Trust, London

HA6 2RN

RECRUITING

East and North Hertfordshire NHS Trust, Lister Hospital, Northwood, Middlesex

SM2 5PT

RECRUITING

The Royal Marsden NHS Foundation Trust, Surry

Sponsors
All Listed Sponsors
lead

Flamingo Therapeutics NV

INDUSTRY